Examples of such statements include but are not limited to statements relating to i Ascendis plans to seek to address the deficiencies identifi ed by the FDA  ii the possibility of a delay in the FDAs final regulatory decision on the TransCon PTH NDA  iii Ascendis intent to continue to make TransCon PTH available to patients participating in its ongoing clinical trials as well as to physicians through its US EAP iv Ascendis expectations regarding a n EAP in Germany  v the timing and results of a European Commission decision on the Marketing Authorisation Application for TransCon PTH vi Ascendis expectations regarding the timing of potential commercial launch of TransCon PTH in Europe if approved  vii Page 3 of 3 Ascendis ability to apply its platform technology to build a leading fully integrated  global biopharmaceutical company and  viii Ascendis use of its TransCon technologies to create new and potentially best inclass therapies